Protective renal effect of dapagliflozin in type 2 diabetes

被引：0
|
作者：
Dobler, Gabriele
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2023年 / 18卷 / 01期
关键词：
D O I：
10.1055/a-1933-5902
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In vorhergehenden Studien wurde bereits nachgewiesen, dass Natrium-Glucose-Cotransporter-2-Inhibitoren (SGLT2-Inhibitoren) das Progressionsrisiko einer moderaten bis schweren albuminurischen Nierenerkrankung mindern. Mosenzon et al. untersuchten in einer Post-hoc-Analyse die Auswirkungen von Dapagliflozin auf die Verschlechterung der Nierenfunktion bei Typ-2-Diabetes. Der Fokus lag auf der Subpopulation von Patient/innen mit niedrigem renalem Risiko.
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
    Hidalgo Santiago, Juan Carlos
    Maraver Delgado, Juan
    Cayon Blanco, Manuel
    Lopez Saez, Juan Bosco
    Gomez-Fernandez, Pablo
    [J]. MEDICINA CLINICA, 2020, 154 (05): : 171 - 174
  • [32] Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
    Kato, Eri T.
    Silverman, Michael G.
    Mosenzon, Ofri
    Zelniker, Thomas A.
    Cahn, Avivit
    Furtado, Remo H. M.
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Bonaca, Marc P.
    Ruff, Christian T.
    Desai, Akshay S.
    Goto, Shinya
    Johansson, Peter A.
    Gause-Nilsson, Ingrid
    Johanson, Per
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2019, 139 (22) : 2528 - 2536
  • [33] THE EFFECTS OF CHRONIC DAPAGLIFLOZIN TREATMENT ON THE RENAL MICROVASCULATURE IN A RAT MODEL OF TYPE 2 DIABETES
    Ow, Connie
    Sukumaran, Vijayakumar
    Ngo, Jennifer
    Du, Cheng Kun
    Fujiwara, Akihiro
    Tsuchimochi, Hirotsugu
    Hosoda, Hiroshi
    Evans, Roger
    Pearson, James
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1301 - 1301
  • [34] Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
    Nguyen, John T.
    Molony, Donald A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (02) : JC5 - JC5
  • [35] THE EFFICACY AND RENAL SAFETY OF SWITCHING FROM DAPAGLIFLOZIN TO EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, Ai-Yu
    Chen, Hung-Chun
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1374 - 1374
  • [36] Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety
    Yu, Pei-Ling
    Yu, You
    Li, Shuang
    Mu, Bai-Chen
    Nan, Ming-Hua
    Pang, Min
    [J]. WORLD JOURNAL OF DIABETES, 2024, 15 (07)
  • [37] Dapagliflozin plus metformin for type 2 diabetes
    不详
    [J]. AFRICAN JOURNAL OF DIABETES MEDICINE, 2010, 18 (02): : 18 - 18
  • [38] Dapagliflozin in patients with type 2 diabetes mellitus
    Filippatos, Theodosios D.
    Liberopoulos, Evangelos N.
    Elisaf, Moses S.
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 29 - 41
  • [39] Correction to: Dapagliflozin: A Review in Type 2 Diabetes
    Sohita Dhillon
    [J]. Drugs, 2019, 79 (18) : 2013 - 2013
  • [40] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Wiviott, S. D.
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Zelniker, T. A.
    Kuder, J. F.
    Murphy, S. A.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Ruff, C. T.
    Gause-Nilsson, I. A. M.
    Fredriksson, M.
    Johansson, P. A.
    Langkilde, A-M.
    Sabatine, M. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 347 - 357
12345